ArticleEuropean urology open science2021
The Role of Cytoreductive Radical Prostatectomy in the Treatment of Newly Diagnosed Low-volume Metastatic Prostate Cancer. Results from the Local Treatment of Metastatic Prostate Cancer (LoMP) Registry.
Article in European urology open science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis.British journal of cancer · 2024Pooled it
- Cytoreductive prostatectomy may improve oncological outcomes in patients with oligometastatic prostate cancer: An updated systematic review and meta-analysis.Investigative and clinical urology · 2023Pooled it
- An Updated Systematic and Comprehensive Review of Cytoreductive Prostatectomy for Metastatic Prostate Cancer.Current oncology (Toronto, Ont.) · 2023Pooled it
- Cytoreductive radical prostatectomy or radiation therapy for metastases prostate cancer: Evidence from meta-analysis.Medicine · 2022Pooled it
- Evaluation of triplet therapy combined with robot-assisted cytoreductive prostatectomy for high-volume metastatic prostate cancer: a multicentre randomised controlled trial protocol.BJU international · 2026Article
- Preoperative ADT combined with docetaxel for conversion therapy in large-volume and unresectable locally advanced or oligometastatic prostate cancer: a multicenter retrospective study (YHCG-001 study).International journal of surgery (London, England) · 2026Article
- Article
- A Cross-Sectional Study on the Sociodemographic Profile of Sickle Cell Disease and Quality of Life in the Pediatric Age Group Among the Tribal Population Of Madhya Pradesh.Journal of pharmacy & bioallied sciences · 2025Article
- Role of Radical Prostatectomy in Oligo-Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Meta-Analysis.Cancers · 2025Review
- Role ofBMC cancer · 2025Article
- [Local therapies for oligometastatic hormone-sensitive prostate cancer].Urologie (Heidelberg, Germany) · 2024Review
- [Metastasis-directed therapy in prostate cancer].Urologie (Heidelberg, Germany) · 2024Review
- Article
- Radical prostatectomy versus radiotherapy as local therapy for primary tumors in patients with oligometastatic prostate cancer.Frontiers in oncology · 2024Article
- Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping.Nature cancer · 2024Article
- Establishing a Role for Radical Prostatectomy in Low-volume Metastatic Disease: From Premise to Proof?European urology open science · 2024Article
- Improved survival of patients with newly diagnosed oligometastatic prostate cancer through intensified multimodal treatment.Frontiers in oncology · 2024Article
- Oligometastatic Prostate Cancer-The Middle Child Syndrome.Journal of clinical medicine · 2023Review
- What is the ideal combination therapy in de novo, oligometastatic, castration-sensitive prostate cancer?World journal of urology · 2023Review
- Clinical Significance of Mesenchymal Circulating Tumor Cells in Patients With Oligometastatic Hormone-Sensitive Prostate Cancer Who Underwent Cytoreductive Radical Prostatectomy.Frontiers in oncology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRadiotherapy to the prostate (RTp) prolongs survival for patients with low-volume, newly diagnosed metastatic prostate cancer (ndmPC).
objectiveto evaluate whether cytoreductive radical prostatectomy (cRP) is equally beneficial as RTp in low-volume ndmPC. DESIGN SETTING AND
participantsA multicenter prospective registry was established in 2014 to observe patients with ndmPC. Eligible patients were offered cRP or RTp. For this study we selected only patients with low-volume ndmPC (
interventioncRP was compared with RTp and NLT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Overall survival (OS), cancer-specific survival (CSS), and local event-free survival (LEFS) were calculated using the Kaplan-Meier method. Factors prognostic for OS were identified using univariate and multivariate Cox regression analysis. RESULTS AND LIMITATIONS: The 2-yr OS was 93%, 100%, and 69%, and 2-yr CSS was 93%, 100%, and 75% for cRP, RTp, and NLT, respectively. The cRP and RTp groups had better OS compared to NLT and there was no significant difference between cRP and RTp. The 2-yr LEFS was 92%, 77%, and 60% for cRP, RTp, and NLT, respectively. The cRP group had better LEFS compared to RTp and NLT, and there was no significant difference between RTp and NLT. Advanced tumor stage, Eastern Cooperative Oncology Group performance status ≥2, and NLT were negative prognostic factors for OS. The main limitation is selection of fitter patients with less advanced tumors for cRP and the small sample size.
conclusionsFor selected patients with low-volume ndmPC, cRP is able to achieve similar OS and CSS to RTp. cRP is effective in preventing local events due to disease progression. PATIENT SUMMARY: Patients with a low volume of newly diagnosed prostate cancer that has spread beyond the prostate gland might benefit from removal of the prostate, which we found was as effective as radiotherapy to the prostate in prolonging survival. Removal of the prostate is effective in preventing urinary problems caused by cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.